Organon & Company
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.74%.
Did OGN Beat Earnings? Q1 2025 Results
Organon delivered a stronger-than-expected first quarter, posting adjusted EPS of $1.02 against a consensus estimate of $0.89, a beat of 14.17%, even as reported revenue of $1.51 billion slipped 6.7% year-over-year under the weight of loss-of-exclusivity headwinds on Atozet in key European markets and ongoing generic pressure across mature products. Revenue edged just above the $1.51 billion consensus by 0.32%, with the U.S. growing 11% to $412 million providing a meaningful counterbalance to broad international declines. The quarter's defining storyline, however, was a sharp dividend reduction from $0.28 to $0.02 per share quarterly, a deliberate pivot toward accelerated deleveraging as the company targets a net leverage ratio below 4.0x by year-end from roughly 4.3x currently. Women's Health was the portfolio's bright spot, with Nexplanon growing 14% on a constant-currency basis and remaining on track for over $1 billion in 2025 revenue, supported by creative marketing efforts targeting younger consumers. Organon affirmed full-year 2025 guidance, including revenue of $6.13 billion to $6.33 billion and adjusted EBITDA margin of 31% to 32%.
- Nexplanon growth of 14% ex-FX driving Women's Health franchise
- Vtama contributing $24M in Q1, on track for $150M full-year target
- Hadlima ramp-up in U.S. since July 2023 launch partially offsetting biosimilar declines
- Favorable Follistim AQ comparison following exit of spin-related interim operating agreement
- Emgality/Rayvow revenue contribution from acquired European licensing rights
- U.S. revenue grew 11% year-over-year
“We have reset our capital allocation priorities to accelerate progress towards deleveraging, enabling a path to achieve a net leverage ratio of below 4.0x by year-end. Over the last year, we have established a leaner, more fit-for-purpose cost structure while increasing revenue contribution from our core growth drivers. By deleveraging more rapidly, we will continue to strengthen the future prospects of the company. Over time, this will position us to execute more of the compelling business development we've done to date, bringing in additional growth drivers to our portfolio, while maintaining lower leverage.”
Organon CEO, on the earnings call
Forward Guidance & Outlook
Organon affirmed its full year 2025 financial guidance: revenue of $6.125B-$6.325B, adjusted gross margin of 60.0%-61.0%, SG&A in the mid-20% range, R&D at upper single-digit percentage, adjusted EBITDA margin of 31.0%-32.0%, interest expense of ~$510M, depreciation of ~$135M, effective non-GAAP tax rate of 22.5%-24.5%, and ~263M fully diluted weighted average shares outstanding. The FX translation headwind of ~$200M is unchanged but with potential upside at current rates. The company expects to generate over $900 million of free cash flow before one-time costs in 2025. Vtama is on track to achieve $150 million revenue for the full year, and Nexplanon is on track for over $1 billion in revenue. The Atozet LOE headwind is expected to persist through Q3 2025. A potential U.S. denosumab biosimilar launch is anticipated in late 2025.
OGN YoY Financials
OGN Revenue by Segment
OGN Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.